<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112523">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01775566</url>
  </required_header>
  <id_info>
    <org_study_id>NVP-EPT-PK-01</org_study_id>
    <nct_id>NCT01775566</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Compare the Pharmacokinetics and Safety of Eperisone HCl SR Tablet 75mg and Myonal Tablet 50mg</brief_title>
  <official_title>A Phase I Clinical Trial to Compare the Pharmacokinetics and Safety of Eperisone HCl SR Tablet 75mg and Myonal Tablet 50mgafter Oral Administration in Healthy Male Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Navipharm Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Navipharm Corporation</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to Evaluate and Compare Safety and Pharmacokinetic of the
      Eperisone HCl SR and Myonal in healthy Korean male adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Myonal: Eperisone Hydrochloride (muscle relaxant)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Crossover, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Auclast, Cmax</measure>
    <time_frame>Eperisone SR 0-24h, Myonal 0-24hr</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf, Tmax, t1/2, Css,min, Tss,max</measure>
    <time_frame>Eperisone SR 0-24hr, Myonal 0-24hr</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">27</enrollment>
  <condition>Low Back Pain</condition>
  <arm_group>
    <arm_group_label>Eperisone SR tablet 75mg, Myonal 50mg</arm_group_label>
    <description>Eperisone SR tablet 75mg Myonal 50mg</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        acute low back pain
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects age between 20 and 55 singed informed consent

        Exclusion Criteria:

          -  Hypotension or hypertension has a history of allergy reaction of this drug or other
             drugs
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoon Y Ran, M.D.Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungpook National University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gyeonggi SMB Growth Accelerating Center</name>
      <address>
        <city>Suwon-si</city>
        <state>Gyeonggi do</state>
        <zip>441-814</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 23, 2013</lastchanged_date>
  <firstreceived_date>January 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Eperisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
